Dare Bioscience faces Nasdaq delisting over equity deficiency

Dare Biosciences, Inc. (NASDAQ: DARE) received a notification from Nasdaq's Listing Qualifications Staff on July 13, 2026, stating that the company no longer complies with Nasdaq Listing Rule 5550(b).

According to the company's Form 10-Q for the period ended March 31, 2026, stockholders' equity fell below the required $2.5 million threshold. As of July 13, 2026, the company also did not meet the alternative compliance standards, which require either $35 million in market value of listed securities or $500,000 in net income from continuing operations.

As a result, Dare Biosciences' common stock is subject to delisting from Nasdaq. The company stated it intends to request a hearing before a Nasdaq Hearing Panel, which would stay any suspension or delisting at least until the panel issues its decision and any extension period expires.

The company noted in a statement that there is no assurance the panel will grant an extension, that compliance will be regained within any such period, or that the company will retain its Nasdaq listing.

You May Also Be Interested In

• Nomura/Instinet Upgrades MR DIY Group M Bhd (MRDIY:MK) to Buy
• Deutsche Bank Downgrades Spire Healthcare (SPI:LN) (SRRHF) to Hold
• JPMorgan Reiterates Overweight Rating on Hindustan Unilever Ltd (HUVR:IN)